The Laboratory of Pulmonary and Exercise Immunology (LABPEI) have identified that an herbal product from Israel (ImmuneCov™/Virlaza™) from Libi Pharm was able to inhibit in 90% the release of harmful pro-inflammatory cytokines from airway epithelial cells (the entrance door) for the coronavirus in vitro, while increased the release of anti-inflammatory cytokines and anti-aging and anti-cancer protein Klotho.

In this study (manuscript under preparation), we were able to demonstrate that ImmuneCov™/Virlaza™ can very efficiently inhibit the “cytokine storm” via inhibition of hyperactivation of airway epithelial cells by coronavirus (Sars-Cov-2).

https://labpei.com.br/hot-news-immunecov-virlaza-2/

Development and research of the company "LibiPharm" - "LibiPharm" Israel.

© 2023 Calpton SIA. All rights reserved.

We accept